Rodt H, Netzel B, Niethammer D, Körbling M, Götze D, Kolb H J, Thiel E, Haas R J, Fliedner T M, Thierfelder S
Transplant Proc. 1977 Mar;9(1):187-91.
The experimental data show that absorption of ATG with liver-kidney homogenate and CLL and LCL cells stepwise removed the hemopoietic toxicity, whereas the specific activity against T lymphocytes remained. Although the mode of action of absorbed ATG could not be tested in the first clinical case, the successful experiments in rodents together with the fact that the incubation treatment was tolerated by the patient may provide a new way of preventing fatal GVH reactions in man.
实验数据表明,用肝肾匀浆以及慢性淋巴细胞白血病(CLL)和淋巴母细胞系(LCL)细胞逐步吸收抗胸腺细胞球蛋白(ATG)可消除造血毒性,而对T淋巴细胞的特异性活性依然存在。尽管在首个临床病例中无法测试吸收型ATG的作用方式,但在啮齿动物身上的成功实验以及患者耐受孵育治疗这一事实,可能为预防人类致命的移植物抗宿主(GVH)反应提供一种新方法。